Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo's Advair Combo Gets Broad Asthma Indication From FDA

Executive Summary

Glaxo Wellcome's Advair Diskus will carry a broad indication for asthma patients requiring combination beta agonist/corticosteroid therapy.

You may also be interested in...



GSK Advair Launch Price Will Be Discount To Separate Asthma Ingredients

GlaxoSmithKline's beta agonist/corticosteroid therapy Advair Diskus will be launched April 16 at a slight discount to the combined cost of its component therapies, fluticasone and salmeterol.

GSK Advair Launch Price Will Be Discount To Separate Asthma Ingredients

GlaxoSmithKline's beta agonist/corticosteroid therapy Advair Diskus will be launched April 16 at a slight discount to the combined cost of its component therapies, fluticasone and salmeterol.

AstraZeneca Symbicort U.S. Filing Awaits Results of Formoterol Trials

A U.S. NDA filing for AstraZeneca's combination asthma therapy Symbicort awaits completion of Phase III trials of the beta agonist (formoterol) component.

Related Content

UsernamePublicRestriction

Register

PS036544

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel